Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 2Phase 3 2Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2

Interventions

Eating 5Standard of Care 4Radiofrequency Ablation 4Exercise 4Endoscopic Mucosal Resection 4Surgical Procedures, Operative 3Radiosurgery 3Adrenalectomy 3lutetium Lu 177 dotatate 2Yoga 2Saline Solution 2Robotic Surgical Procedures 2Resistance Training 2Proton Therapy 2Propofol 2Palliative Care 2Octreotide 2Magnetic Resonance Imaging 2Lutetium-177 2Liquid Biopsy 2Interviews as Topic 2Hydrocortisone 2Diet, Mediterranean 2Diet 2Desflurane 2Data Collection 2Conversion to Open Surgery 2Control Groups 2Calcium 23-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Lutetium-177 × Endocrine × Clear all
NCT04790708 2021-03-10

FENET-2016

University Hospital of Ferrara

Phase NA Unknown
250 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Instituto Nacional de Cancerologia, Columbia

Phase NA Completed
39 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡